World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

Abstract

ANALYTICAL METHOD DEVELOPMENT AND VALIDATION OF DABIGATRAN ETEXILATE IN PURE AND DOSAGE FORMS BY USING RP-HPLC METHOD

Sk. Karishma*, Ch. M. M. Prasada Rao and D. Dhachinamoorthi

ABSTRACT

A simple, precise, analytical method was developed for Dabigatran Etexilate in pure and dosage forms by using RP-HPLC method analysis initial chromatographic conditions Mobile phase Buffer: ACN: Water in gradient method, Zodiac, C18, 100×4.6mm, 3.5? column, Flow rate 1.0 ml/min and temperature was ambient, eluent was scanned with UV- VIS detector in system and it showed maximum absorbance at 310 nm. As the mobile phase content is allowed in gradient performance Dabigatran Etexilate got eluted with good peak symmetric properties. The retention time for Dabigatran Etexilate was found to be 4.767min respectively. System suitability parameters were studied by injecting the standard six times and results were well under the acceptance criteria. Linearity study was carried out between 50%, 100% and 150 % levels, R2 value was found to be as 0.999. By using above method assay of marketed formulation was carried out, 99.92% for Dabigatran Etexilate was present. Full length method was not performed; if it is done this method can be used for routine analysis of Dabigatran Etexilate.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR